New Zealand markets closed

NatureWise Biotech & Medicals Corporation (4732.TWO)

Taipei Exchange - Taipei Exchange Delayed price. Currency in TWD
Add to watchlist
25.25-0.70 (-2.70%)
At close: 02:53PM CST
Currency in TWD

Valuation measures4

Market cap (intra-day) 1.29B
Enterprise value 829.28M
Trailing P/E 131.25
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)8.18
Price/book (mrq)2.04
Enterprise value/revenue 5.18
Enterprise value/EBITDA 40.67

Trading information

Stock price history

Beta (5Y monthly) 0.76
52-week change 3-13.93%
S&P500 52-week change 326.24%
52-week high 332.00
52-week low 322.05
50-day moving average 325.94
200-day moving average 325.75

Share statistics

Avg vol (3-month) 342.51k
Avg vol (10-day) 356.47k
Shares outstanding 549.29M
Implied shares outstanding 649.85M
Float 8N/A
% held by insiders 1N/A
% held by institutions 1N/A
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.5
Forward annual dividend yield 41.90%
Trailing annual dividend rate 30.20
Trailing annual dividend yield 30.77%
5-year average dividend yield 4N/A
Payout ratio 4250.00%
Dividend date 3N/A
Ex-dividend date 429 Aug 2023
Last split factor 21060:1000
Last split date 313 Sept 2021

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 6.32%
Operating margin (ttm)2.74%

Management effectiveness

Return on assets (ttm)0.31%
Return on equity (ttm)1.59%

Income statement

Revenue (ttm)160.14M
Revenue per share (ttm)3.25
Quarterly revenue growth (yoy)-17.80%
Gross profit (ttm)N/A
EBITDA 13.85M
Net income avi to common (ttm)10.12M
Diluted EPS (ttm)0.20
Quarterly earnings growth (yoy)-46.30%

Balance sheet

Total cash (mrq)475.26M
Total cash per share (mrq)9.66
Total debt (mrq)7.78M
Total debt/equity (mrq)1.23%
Current ratio (mrq)11.55
Book value per share (mrq)12.88

Cash flow statement

Operating cash flow (ttm)62.2M
Levered free cash flow (ttm)5.19M